Skip to content

Discontinued — last reported Q1 '26

D&A at other companies

Zymeworks logo
ZymeworksZYME
$176K-89.1%
Xencor logo
XencorXNCR
$2.57M-4.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$661K+13.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$6.84M+28.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$2.71M0.0%
Roivant Sciences logo
Roivant SciencesROIV

Segments

By segment

See full
Single Reportable$892K+64.0%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's D&A?
XOMA Corporation (XOMA) reported D&A of $892K in Q1 2026.
How has XOMA Corporation's D&A changed year-over-year?
XOMA Corporation's D&A increased by 64.0% year-over-year, from $544K to $892K.
What is the long-term trend for XOMA Corporation's D&A?
Over 3 years (2022 to 2025), XOMA Corporation's D&A has grown at a 212.5% compound annual growth rate (CAGR), from $97K to $2.96M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.